United Therapeutics Corporation (UTHR)

Acerca de United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Al 3 de noviembre de 2026, la acción de United Therapeutics Corporation (UTHR) subió a $600.42, un alza de 0.72% (+$4.29) frente al cierre anterior. En la sesión, las acciones han operado entre $596.14 y $606.16. Eso ubica a UTHR cerca del máximo de su rango de 52 semanas, de $430.02 a $609.99. United Therapeutics Corporation opera en el sector de pharmaceutical preparations y tiene una capitalización de mercado de aproximadamente $25.57 mil millones, con cerca de 280.8 mil acciones negociadas.

Últimas noticias de UTHR

• iShares Core S&P Mid-Cap (IJH) Adds Okta and TechnipFMC on Oct. 29Yahoo Finance· 2 nov, 6:06 a.m. ETIJH
• SGIOY vs. UTHR: Which Stock Is the Better Value Option?Yahoo Finance· 30 oct, 10:40 a.m. ET
• OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue EstimatesYahoo Finance· 30 oct, 7:50 a.m. ETOABI
• Why Did Insmed Stock Jump?trefis.com· 30 oct, 7:15 a.m. ET
• United Therapeutics (UTHR) Cleared To Start Trial For New Pulmonary Hypertension TherapyYahoo Finance· 29 oct, 4:12 p.m. ET
• Insmed Soars 12% on $400 Million Brinsupri Quarter as U.S. Launch “Continues to Exceed Expectations”tikr.com· 29 oct, 2:40 p.m. ET
• Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to DeclineYahoo Finance· 29 oct, 9:00 a.m. ETCOLL
• United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatmentinvestorshub.advfn.com· 28 oct, 11:26 a.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de UTHR en un solo lugar? Crea una cuenta gratis →

• $MNKD $UTHR reporting Q3 tomorrow morning should provide a bit of insight to our Thursday report. Exciting times ahead.

  @amsteliam· 3 nov, 12:14 p.m. ET· Alcista

• @Myd273 $UTHR $MNKD SMI is likely being developed for COPD, not primarily to recapture the 3% who drop TreT due to cough. Credit: @ItzaFugazi

  @clan2pointOh· 2 nov, 7:40 p.m. ET· Alcista

• $MNKD $UTHR | AERO LAB INSTITUTIONAL RESEARCH JEFFERIES LONDON: THREE PRESENTATIONS, TWO COMPANIES, ONE INVESTMENT THESIS November 16–18 could offer an important opportunity to evaluate the next phase of MannKind’s growth story. The sequence: • Nov 16: MNKD management presenta…

  @Michaelluh· 2 nov, 11:08 a.m. ET· Alcista

• @Kuka @Nakom SMI is not being resurrected to capture the mere 3% of Tyvaso DPI users who stop using due to cough, but, instead, is being created to capture the COPD market; still years away from availability. $UTHR wants to be all products for all patients.

  @clan2pointOh· 2 nov, 8:44 a.m. ET· Alcista

• $MNKD $UTHR .....nicely done! https://x.com/st_boardroomx/status/2115799054156251351?s=43

  @Outcomes· 31 oct, 1:08 p.m. ET

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →